The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Bismuth-213     bismuth

Synonyms: AC1O3TJ3, 213Bi, 15776-20-2, Bismuth, isotope of mass 213
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of bismuth


High impact information on bismuth


Chemical compound and disease context of bismuth

  • We have recently demonstrated the feasibility of using RIT for treating murine cryptococcosis using a monoclonal antibody to Crypto-coccus neoformans capsular glucuronoxylomannan labeled with Bismuth-213 or Rhenium-188 [10].
  • METHODS AND FINDINGS: Antibodies to HIV-1 envelope glycoproteins gp120 and gp41 labeled with radioisotopes bismuth 213 ((213)Bi) and rhenium 188 ((188)Re) selectively killed chronically HIV-1-infected human T cells and acutely HIV-1-infected human peripheral blood mononuclear cells (hPBMCs) in vitro [11].

Biological context of bismuth


Associations of bismuth with other chemical compounds


Analytical, diagnostic and therapeutic context of bismuth


  1. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Zhang, M., Yao, Z., Garmestani, K., Axworthy, D.B., Zhang, Z., Mallett, R.W., Theodore, L.J., Goldman, C.K., Brechbiel, M.W., Carrasquillo, J.A., Waldmann, T.A. Blood (2002) [Pubmed]
  2. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. McDevitt, M.R., Barendswaard, E., Ma, D., Lai, L., Curcio, M.J., Sgouros, G., Ballangrud, A.M., Yang, W.H., Finn, R.D., Pellegrini, V., Geerlings, M.W., Lee, M., Brechbiel, M.W., Bander, N.H., Cordon-Cardo, C., Scheinberg, D.A. Cancer Res. (2000) [Pubmed]
  3. In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells. Ranson, M., Tian, Z., Andronicos, N.M., Rizvi, S., Allen, B.J. Breast Cancer Res. Treat. (2002) [Pubmed]
  4. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Supiot, S., Faivre-Chauvet, A., Couturier, O., Heymann, M.F., Robillard, N., Kraeber-Bodéré, F., Morandeau, L., Mahé, M.A., Chérel, M. Cancer (2002) [Pubmed]
  5. Preclinical targeted alpha therapy for subcutaneous melanoma. Allen, B.J., Rizvi, S.M., Tian, Z. Melanoma Res. (2001) [Pubmed]
  6. Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Bethge, W.A., Wilbur, D.S., Storb, R., Hamlin, D.K., Santos, E.B., Brechbiel, M.W., Fisher, D.R., Sandmaier, B.M. Blood (2003) [Pubmed]
  7. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein. Miederer, M., Seidl, C., Beyer, G.J., Charlton, D.E., Vranjes-Duric, S., Comor, J.J., Huber, R., Nikula, T., Apostolidis, C., Schuhmacher, C., Becker, K.F., Senekowitsch-Schmidtke, R. Radiat. Res. (2003) [Pubmed]
  8. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Kennel, S.J., Stabin, M., Roeske, J.C., Foote, L.J., Lankford, P.K., Terzaghi-Howe, M., Patterson, H., Barkenbus, J., Popp, D.M., Boll, R., Mirzadeh, S. Radiat. Res. (1999) [Pubmed]
  9. Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Abbas Rizvi, S.M., Li, Y., Song, E.Y., Qu, C.F., Raja, C., Morgenstern, A., Apostolidis, C., Allen, B.J. Cancer Biol. Ther. (2006) [Pubmed]
  10. Treatment of infection with radiolabeled antibodies. Dadachova, E., Casadevall, A. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceu... (2006) [Pubmed]
  11. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Dadachova, E., Patel, M.C., Toussi, S., Apostolidis, C., Morgenstern, A., Brechbiel, M.W., Gorny, M.K., Zolla-Pazner, S., Casadevall, A., Goldstein, H. PLoS Med. (2006) [Pubmed]
  12. In vivo studies of pharmacokinetics and efficacy of Bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27. Rizvi, S.M., Qu, C.F., Song, Y.J., Raja, C., Allen, B.J. Cancer Biol. Ther. (2005) [Pubmed]
  13. Antibody-based treatment of acute myeloid leukaemia. Mulford, D.A., Jurcic, J.G. Expert opinion on biological therapy. (2004) [Pubmed]
  14. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Bethge, W.A., Wilbur, D.S., Storb, R., Hamlin, D.K., Santos, E.B., Brechbiel, M.W., Sandmaier, B.M. Transplantation (2004) [Pubmed]
  15. Antibody therapy in acute myeloid leukemia: current status and future directions. Burke, J.M., Jurcic, J.G. Clinical lymphoma. (2002) [Pubmed]
WikiGenes - Universities